


=> d l1  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 07:46:41 ON 27 JUL 2004)

FILE 'REGISTRY' ENTERED AT 07:46:54 ON 27 JUL 2004


L1 STRUCTURE UPLOADED  
L2 1 S L1  
L3 50 S L1 FULL  
L4 50 S L3 AND CAPLUS/LC  
L5 0 S L3 AND CAOLD/LC  
L6 0 S L3 AND REF.CAPLUS>10

FILE 'CAPLUS' ENTERED AT 07:52:31 ON 27 JUL 2004

L7 3 S L3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2002:483072 CAPLUS  
 DOCUMENT NUMBER: 137:47109  
 TITLE: Preparation of trisubstituted indole derivatives for  
 inhibiting neoplastic cells  
 INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.  
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA  
 SOURCE: U.S., 76 pp., Cont.-in-part of U. S. 6,046,199.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

| PATENT NO.             | KIND             | DATE     | APPLICATION NO. | DATE        |
|------------------------|------------------|----------|-----------------|-------------|
| US 6410584             | B1               | 20020625 | US 1998-199860  | 19981125    |
| US 6046199             | A                | 20000404 | US 1998-7098    | 19980114    |
| US 2002143022          | A1               | 20021003 | US 2002-71639   | 20020207    |
| PRIORITY APPLN. INFO.: |                  |          | US 1998-7098    | A2 19980114 |
|                        |                  |          | US 1998-199860  | A3 19981125 |
| OTHER SOURCE(S):       | MARPAT 137:47109 |          |                 |             |
| GI                     |                  |          |                 |             |



AB Title compds. I [R1-3 = H, alkyl, alkylthio alkoxy, with the proviso that R1-3 are not simultaneously hydrogen atoms; R4 = H, alkyl; R5 = carboxy, an esterified carboxy group, or an amidated carboxy group] were prepared For instance, 6-methoxycarbonyl-2-methylindole was N-alkylated with 2-chlorobenzyl bromide (DMF, K<sub>2</sub>CO<sub>3</sub>, 80°C, 18 h); the product saponified and the resulting acid coupled to benzenesulfonamide (DMF, CDI, DBU) to afford II. I are used for inhibiting the growth of neoplastic cells (no data).


IT **206065-16-9P**, 5-((Benzenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole **206065-31-8P**, 3-(2,4-Dichlorobenzyl)-5-[[[(4-methoxybenzene)sulfonyl]carbamoyl]-2-methylindole **206065-53-4P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-methylbenzene)sulfonyl]carbamoyl]indole **206065-55-6P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-nitrobenzene)sulfonyl]carbamoyl]indole **206065-57-8P**, 5-[[[(4-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-59-0P**, 5-[[[(3-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-61-4P**, 5-[[[(2-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole

yl]-3-(2,4-dichlorobenzyl)-2-methylindole 206065-63-6P,  
 3-(2,4-Dichlorobenzyl)-5-[[4-(fluorobenzene)sulfonyl]carbamoyl]-2-  
 methylindole 206065-64-7P, 3-(2,4-Dichlorobenzyl)-2-methyl-5-  
 [[2-naphthalene)sulfonyl]carbamoyl]indole 206065-65-8P,  
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[naphthalen-1-  
 yl)sulfonyl]carbamoyl]indole 206065-66-9P, 3-(2,4-  
 Dichlorobenzyl)-2-methyl-5-[[2-methylbenzene)sulfonyl]carbamoyl]indole  
 206065-68-1P, 5-(((4-Bromobenzene)sulfonyl)carbamoyl)-3-(2,4-  
 dichlorobenzyl)-2-methylindole 206065-70-5P,  
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-(vinylbenzene)sulfonyl]carbamoyl]ind  
 ole 206065-71-6P, 5-[[4-(Phenylazo)benzene)sulfonyl]carbamoyl]-  
 3-(2,4-dichlorobenzyl)-2-methylindole 206065-72-7P,  
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-(trifluoromethylbenzene)sulfonyl]car  
 bamoyl]indole 206065-74-9P, 3-(2,4-Dichlorobenzyl)-5-[[3,4-  
 dimethoxybenzene)sulfonyl]carbamoyl]-2-methylindole 206065-76-1P  
 , 5-[[4-(tert-Butylbenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-  
 methylindole 206065-77-2P, 3-(2,4-Dichlorobenzyl)-2-methyl-5-  
 [[3-methylbenzene)sulfonyl]carbamoyl]indole 206065-81-8P,  
 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-phenylbenzene)sulfonyl]carbamoyl]in  
 dole 206065-83-0P, 5-((Benzenesulfonyl)carbamoyl)-3-[2-chloro-4-  
 phenylbenzyl]-2-methylindole 206065-85-2P, 5-[[4-(n-  
 Butylbenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole  
 206065-86-3P, 5-[[4-(Butoxy)benzene)sulfonyl]carbamoyl]-3-(2,4-  
 dichlorobenzyl)-2-methylindole 206065-96-5P,  
 3-[(1-Bromonaphthalen-2-yl)methyl]-2-methyl-5-[[4-  
 vinylbenzene)sulfonyl]carbamoyl]indole 206065-98-7P,  
 5-[[Benzenesulfonyl]carbamoyl]-3-[(1-bromonaphthalen-2-yl)methyl]-2-  
 methylindole 206066-00-4P, 3-[2-Chloro-4-phenylbenzyl]-2-methyl-  
 5-[[4-(vinylbenzene)sulfonyl]carbamoyl]indole 206066-02-6P,  
 3-[2-Chloro-4-phenylbenzyl]-2-methyl-5-[[4-methylphenylsulfonyl]carbamoyl]  
 indole 438003-21-5P, 3-(2,4-Dichlorobenzyl)-5-((2,5-  
 dimethylbenzene)sulfonyl)carbamoyl]-2-methylindole 438003-26-0P,  
 3-(2,4-Dichlorobenzyl)-5-[[4-ethylbenzene)sulfonyl]carbamoyl]-2-  
 methylindole 438003-36-2P, 3-[(1-Bromonaphthalen-2-yl)methyl]-2-  
 methyl-5-[[p-toluenesulfonyl]carbamoyl]indole  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(drug; preparation of trisubstituted indole derivs. for inhibiting  
 neoplastic cells)


RN 206065-16-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-  
 (phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-31-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-  
 methoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-53-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-55-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-57-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-59-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(3-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-61-4 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(2-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-63-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-

fluorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-64-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-65-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-66-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-68-1 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-bromophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-70-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-71-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(phenylazo)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-72-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-74-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(3,4-dimethoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-76-1 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)






RN 206065-77-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(3-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-81-8 CAPLUS


CN 1H-Indole-5-carboxamide, N-([1,1'-biphenyl]-4-ylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-83-0 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-

N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-85-2 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butylphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-86-3 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butoxyphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-96-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-98-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206066-00-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206066-02-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 438003-21-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2,5-dimethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 438003-26-0 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 438003-36-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(2-

methylphenyl)sulfonyl] - (9CI) (CA INDEX NAME)



REFERENCE COUNT:

18

THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:239201 CAPLUS

DOCUMENT NUMBER: 128:294695

TITLE: Preparation and formulation of indole derivatives as hypoglycemics and phosphodiesterase 5 inhibitors

INVENTOR(S): Yamasaki, Noritsugu; Imoto, Takafumi; Murai, Yoshiyuki; Hiramura, Takahiro; Onomura, Osamu; Nishikawa, Masahiro; Oku, Teruo; Sawada, Kouzou; Kayakiri, Hiroshi; et al.

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 184 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE           | APPLICATION NO. | DATE     |
|---|------|----------------|-----------------|----------|
| WO 9815530  | A1   | 19980416       | WO 1997-JP3592  | 19971007 |
| W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NZ, RU, SG, TR, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM |      |                |                 |          |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, PT, SE                            |      |                |                 |          |
| AU 9744005  | A1   | 19980505       | AU 1997-44005   | 19971007 |
| ZA 9708998  | A    | 19980420       | ZA 1997-8998    | 19971008 |
| PRIORITY APPLN. INFO.:  |      | JP 1996-287676 | A               | 19961008 |
|   |      | JP 1997-187536 | A               | 19970627 |
|   |      | WO 1997-JP3592 | W               | 19971007 |

OTHER SOURCE(S): MARPAT 128:294695

GI



AB The title compds. I [R1 - R3 = H, alkyl, etc.; a proviso is given; R4 = H,

alkyl; R5 = carboxy, etc.] are prepared I are useful as remedies for impaired glucose tolerance, diabetes, complication of diabetes, insulin resistant syndrome, hyperlipidemia, atherosclerosis, cardiovascular diseases, hyperglycemia, hypertension; diseases characterized by angina pectoris, high blood pressure, pulmonary hypertension, congestive heart failure, glomerular diseases, tubular interstitial diseases, renal insufficiency, atherosclerosis, angiostenosis, peripheral vascular diseases, cerebral stroke, chronic reversible obstructive diseases, allergic rhinitis, urticaria, glaucoma or intestinal motility disorders; sexual impotence, osteoporosis, nephritis, cancerous cachexia or post-PTCA reconstruction. The title compound II at 10 mg/kg gave 46% decrease of blood sugar in mice.


IT 206065-16-9P 206065-31-8P 206065-53-4P  
 206065-55-6P 206065-57-8P 206065-59-0P  
 206065-61-4P 206065-63-6P 206065-64-7P  
 206065-65-8P 206065-66-9P 206065-67-0P  
 206065-68-1P 206065-70-5P 206065-71-6P  
 206065-72-7P 206065-74-9P 206065-76-1P  
 206065-77-2P 206065-81-8P 206065-83-0P  
 206065-84-1P 206065-85-2P 206065-86-3P  
 206065-96-5P 206065-97-6P 206065-98-7P  
 206066-00-4P 206066-02-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indole derivs. as hypoglycemics and phosphodiesterase 5 inhibitors)


RN 206065-16-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-31-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-methoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-53-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-55-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-57-8 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(4-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)






RN 206065-59-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(3-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-61-4 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(2-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-63-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-fluorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-64-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-65-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-66-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-67-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2,6-dimethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-68-1 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-bromophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-70-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-71-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(phenylazo)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-72-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 206065-74-9 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(3,4-dimethoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-76-1 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[[4-(1,1-

dimethylethyl)phenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-77-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(3-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-81-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-([1,1'-biphenyl]-4-ylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-83-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-84-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-85-2 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butylphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-86-3 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butoxyphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-96-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-97-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-98-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206066-00-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206066-02-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

53

THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT